Telehealth provider Hims began marketing a compounded, pill-form version of Novo Nordisk’s Wegovy and similar GLP-1 therapies, sparking immediate regulatory and legal pushback. Novo and other manufacturers have threatened litigation, arguing these products are unapproved and unsafe. The FDA has publicly signaled intent to take action against non‑FDA‑approved GLP‑1 products, elevating enforcement risk for telehealth compounding models. The development matters because it tests legal boundaries around compounding and distribution of high‑demand obesity drugs and could reshape how telehealth companies source and sell GLP‑1 treatments. Regulators cited product safety and manufacturing standards as key concerns; manufacturers cited intellectual property and approval pathway protections. For industry readers, expect rapid regulatory and legal activity, potential recalls or enforcement letters, and closer scrutiny of compounding supply chains.